{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:26:25Z","timestamp":1781951185598,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"DOI":"10.7759\/cureus.89954","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T06:58:46Z","timestamp":1755068326000},"source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of Sitagliptin and Empagliflozin Combination Therapy in a Patient With Charcot-Marie-Tooth Disease and Comorbid Diabetes Mellitus: A Case Report"],"prefix":"10.7759","author":[{"given":"Makoto","family":"Wada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amika","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Toriumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Yamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2025.2470980","article-title":"Charcot-Marie-Tooth disease: a review of clinical developments and its management - what's new in 2025?","volume":"25","author":"De Grado A","year":"2025","unstructured":"De Grado A, Serio M, Saveri P, Pisciotta C, Pareyson D. Charcot-Marie-Tooth disease: a review of clinical developments and its management - what's new in 2025?. Expert Rev Neurother. 2025, 25:427-42. 10.1080\/14737175.2025.2470980","journal-title":"Expert Rev Neurother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.1974.tb00638.x","article-title":"Genetic and clinical aspects of Charcot-Marie-Tooth's disease","volume":"6","author":"Skre H","year":"1974","unstructured":"Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet. 1974, 6:98-118. 10.1111\/j.1399-0004.1974.tb00638.x","journal-title":"Clin Genet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/TACG.S69969","article-title":"The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management","volume":"8","author":"Hoyle JC","year":"2015","unstructured":"Hoyle JC, Isfort MC, Roggenbuck J, Arnold WD. The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management. Appl Clin Genet. 2015, 8:235-43. 10.2147\/TACG.S69969","journal-title":"Appl Clin Genet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23775","article-title":"Inherited neuropathies: clinical overview and update","volume":"48","author":"Klein CJ","year":"2013","unstructured":"Klein CJ, Duan X, Shy ME. Inherited neuropathies: clinical overview and update. Muscle Nerve. 2013, 48:604-22. 10.1002\/mus.23775","journal-title":"Muscle Nerve"},{"key":"ref5","article-title":"Characteristics of demyelinating Charcot-Marie-Tooth disease with concurrent diabetes mellitus","volume":"7","author":"Yu Z","year":"2014","unstructured":"Yu Z, Wu X, Xie H, et al.. Characteristics of demyelinating Charcot-Marie-Tooth disease with concurrent diabetes mellitus. Int J Clin Exp Pathol. 2014, 7:4329-38.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2013.08.611","article-title":"Charcot-Marie-Tooth disease: an overview of genotypes, phenotypes, and clinical management strategies","volume":"6","author":"El-Abassi R","year":"2014","unstructured":"El-Abassi R, England JD, Carter GT. Charcot-Marie-Tooth disease: an overview of genotypes, phenotypes, and clinical management strategies. PM R. 2014, 6:342-55. 10.1016\/j.pmrj.2013.08.611","journal-title":"PM R"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00626","article-title":"Rate of changes in CMT neuropathy and examination scores in Japanese adult CMT1A patients","volume":"11","author":"Kitani-Morii F","year":"2020","unstructured":"Kitani-Morii F, Noto YI, Tsuji Y, Shiga K, Mizuta I, Nakagawa M, Mizuno T. Rate of changes in CMT neuropathy and examination scores in Japanese adult CMT1A patients. Front Neurol. 2020, 11:626. 10.3389\/fneur.2020.00626","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143419","article-title":"Charcot-Marie-Tooth: from molecules to therapy","volume":"20","author":"Morena J","year":"2019","unstructured":"Morena J, Gupta A, Hoyle JC. Charcot-Marie-Tooth: from molecules to therapy. Int J Mol Sci. 2019, 20:10.3390\/ijms20143419","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0092-1","article-title":"Diabetic neuropathy","volume":"5","author":"Feldman EL","year":"2019","unstructured":"Feldman EL, Callaghan BC, Pop-Busui R, et al.. Diabetic neuropathy. Nat Rev Dis Primers. 2019, 5:41. 10.1038\/s41572-019-0092-1","journal-title":"Nat Rev Dis Primers"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13574","article-title":"Diabetes coexistent with Charcot-Marie-Tooth disease presenting as a recurrent foot ulcer misdiagnosed as diabetic foot: a case report","volume":"12","author":"Yan Z","year":"2021","unstructured":"Yan Z, Chen D, Yao L, Wang C, Ran XW. Diabetes coexistent with Charcot-Marie-Tooth disease presenting as a recurrent foot ulcer misdiagnosed as diabetic foot: a case report. J Diabetes Investig. 2021, 12:2099-101. 10.1111\/jdi.13574","journal-title":"J Diabetes Investig"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2008.00196.x","article-title":"Diabetes mellitus exacerbates motor and sensory impairment in CMT1A","volume":"13","author":"Sheth S","year":"2008","unstructured":"Sheth S, Francies K, Siskind CE, Feely SM, Lewis RA, Shy ME. Diabetes mellitus exacerbates motor and sensory impairment in CMT1A. J Peripher Nerv Syst. 2008, 13:299-304. 10.1111\/j.1529-8027.2008.00196.x","journal-title":"J Peripher Nerv Syst"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1017\/s0317167100010398","article-title":"Charcot ankle arthropathy in CMT1A exacerbated by type 2 diabetes mellitus","volume":"37","author":"Parks NE","year":"2010","unstructured":"Parks NE, Benstead TJ. Charcot ankle arthropathy in CMT1A exacerbated by type 2 diabetes mellitus. Can J Neurol Sci. 2010, 37:419-21. 10.1017\/s0317167100010398","journal-title":"Can J Neurol Sci"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2990.1997.tb01306.x","article-title":"Hypertrophic neuropathy: atypical appearances resulting from the combination of type I hereditary motor and sensory neuropathy and diabetes mellitus","volume":"23","author":"Thomas PK","year":"1997","unstructured":"Thomas PK, King RH, Bradley JL. Hypertrophic neuropathy: atypical appearances resulting from the combination of type I hereditary motor and sensory neuropathy and diabetes mellitus. Neuropathol Appl Neurobiol. 1997, 23:348-51.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref14","article-title":"[A case of Charcot-Marie-Tooth disease (CMT) type 1 complicated by diabetes mellitus (DM) showing bilateral phrenic nerve palsy]","volume":"42","author":"Takakura Y","year":"2002","unstructured":"Takakura Y, Furuya H, Yamashita K, et al.. [A case of Charcot-Marie-Tooth disease (CMT) type 1 complicated by diabetes mellitus (DM) showing bilateral phrenic nerve palsy]. Rinsho Shinkeigaku. 2002, 42:320-2.","journal-title":"Rinsho Shinkeigaku"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2003.009173.x","article-title":"Marked improvement of glycaemic control with pioglitazone in a type 2 diabetic patient associated with Charcot-Marie-Tooth disease","volume":"20","author":"Ota T","year":"2003","unstructured":"Ota T, Osawa K. Marked improvement of glycaemic control with pioglitazone in a type 2 diabetic patient associated with Charcot-Marie-Tooth disease. Diabet Med. 2003, 20:420-1. 10.1046\/j.1464-5491.2003.009173.x","journal-title":"Diabet Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7547\/1010349","article-title":"Charcot-Marie-Tooth disease complicating type 2 diabetes","volume":"101","author":"Win HH","year":"2011","unstructured":"Win HH, Davenport C, Delaney S, Kelly M, Smith D. Charcot-Marie-Tooth disease complicating type 2 diabetes. J Am Podiatr Med Assoc. 2011, 101:349-52. 10.7547\/1010349","journal-title":"J Am Podiatr Med Assoc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ca.22653","article-title":"Charcot-Marie-Tooth 1A: a narrative review with clinical and anatomical perspectives","volume":"29","author":"McGrath MC","year":"2016","unstructured":"McGrath MC. Charcot-Marie-Tooth 1A: a narrative review with clinical and anatomical perspectives. Clin Anat. 2016, 29:547-54. 10.1002\/ca.22653","journal-title":"Clin Anat"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000472166","article-title":"Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study","volume":"4","author":"Nelis E","year":"1996","unstructured":"Nelis E, Van Broeckhoven C, De Jonghe P, et al.. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet. 1996, 4:25-33. 10.1159\/000472166","journal-title":"Eur J Hum Genet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000237","article-title":"Update on Charcot-Marie-Tooth disease","volume":"28","author":"Gutmann L","year":"2015","unstructured":"Gutmann L, Shy M. Update on Charcot-Marie-Tooth disease. Curr Opin Neurol. 2015, 28:462-7. 10.1097\/WCO.0000000000000237","journal-title":"Curr Opin Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1502783","article-title":"A case report of a MODY6 patient coexistence with Charcot-Marie-Toothe 1A syndrome","volume":"16","author":"Wang J","year":"2025","unstructured":"Wang J, Wang C, Chen Y, Qi S, Wang M. A case report of a MODY6 patient coexistence with Charcot-Marie-Toothe 1A syndrome. Front Endocrinol (Lausanne). 2025, 16:1502783. 10.3389\/fendo.2025.1502783","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-27. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2023.10.004","article-title":"Sodium-glucose co-transporter 2 inhibitors and sarcopenia: a\u00a0controversy that must be solved","volume":"42","author":"Afsar B","year":"2023","unstructured":"Afsar B, Afsar RE. Sodium-glucose co-transporter 2 inhibitors and sarcopenia: a\u00a0controversy that must be solved. Clin Nutr. 2023, 42:2338-52. 10.1016\/j.clnu.2023.10.004","journal-title":"Clin Nutr"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1203666","article-title":"Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Zhang S","year":"2023","unstructured":"Zhang S, Qi Z, Wang Y, Song D, Zhu D. Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023, 14:1203666. 10.3389\/fendo.2023.1203666","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15249","article-title":"Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u226565\u2009years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY)","volume":"25","author":"Yabe D","year":"2023","unstructured":"Yabe D, Shiki K, Homma G, Meinicke T, Ogura Y, Seino Y. Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u226565\u2009years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY). Diabetes Obes Metab. 2023, 25:3538-48. 10.1111\/dom.15249","journal-title":"Diabetes Obes Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12402","article-title":"Increased grip strength with sodium-glucose cotransporter 2","volume":"8","author":"Sano M","year":"2016","unstructured":"Sano M, Meguro S, Kawai T, Suzuki Y. Increased grip strength with sodium-glucose cotransporter 2. J Diabetes. 2016, 8:736-7. 10.1111\/1753-0407.12402","journal-title":"J Diabetes"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2884","article-title":"Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: exploring human metabolites associated with visceral fat reduction","volume":"43","author":"Tsukagoshi-Yamaguchi A","year":"2023","unstructured":"Tsukagoshi-Yamaguchi A, Koshizaka M, Ishibashi R, et al.. Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: exploring human metabolites associated with visceral fat reduction. Pharmacotherapy. 2023, 43:1317-26. 10.1002\/phar.2884","journal-title":"Pharmacotherapy"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13340","article-title":"Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type\u00a02 diabetes mellitus: subanalysis of a prospective, randomized, controlled study (PRIME-V study)","volume":"12","author":"Koshizaka M","year":"2021","unstructured":"Koshizaka M, Ishikawa K, Ishibashi R, et al.. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type\u00a02 diabetes mellitus: subanalysis of a prospective, randomized, controlled study (PRIME-V study). J Diabetes Investig. 2021, 12:200-6. 10.1111\/jdi.13340","journal-title":"J Diabetes Investig"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124952","article-title":"Hyperglycemia induces skeletal muscle atrophy via a WWP1\/KLF15 axis","volume":"4","author":"Hirata Y","year":"2019","unstructured":"Hirata Y, Nomura K, Senga Y, et al.. Hyperglycemia induces skeletal muscle atrophy via a WWP1\/KLF15 axis. JCI Insight. 2019, 4:10.1172\/jci.insight.124952","journal-title":"JCI Insight"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/377501-effectiveness-of-sitagliptin-and-empagliflozin-combination-therapy-in-a-patient-with-charcot-marie-tooth-disease-and-comorbid-diabetes-mellitus-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T06:58:47Z","timestamp":1755068327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/377501-effectiveness-of-sitagliptin-and-empagliflozin-combination-therapy-in-a-patient-with-charcot-marie-tooth-disease-and-comorbid-diabetes-mellitus-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.89954","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}